EP3903805A4 - Immunopotentiating or anticancer activity-augmenting composition comprising mal-expressed stem cell like memory t cell as active ingredient - Google Patents

Immunopotentiating or anticancer activity-augmenting composition comprising mal-expressed stem cell like memory t cell as active ingredient Download PDF

Info

Publication number
EP3903805A4
EP3903805A4 EP19902677.4A EP19902677A EP3903805A4 EP 3903805 A4 EP3903805 A4 EP 3903805A4 EP 19902677 A EP19902677 A EP 19902677A EP 3903805 A4 EP3903805 A4 EP 3903805A4
Authority
EP
European Patent Office
Prior art keywords
cell
immunopotentiating
mal
memory
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19902677.4A
Other languages
German (de)
French (fr)
Other versions
EP3903805A1 (en
Inventor
Sun Hee Heo
Gyungyub GONG
Hee Jin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neogentc Corp Convergence Innovation Building Asan Institute For Life Sciences Pungnap Dong
Original Assignee
Neogentc Corp Convergence Innovation Building Asan Institute For Life Sciences Pungnap Dong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neogentc Corp Convergence Innovation Building Asan Institute For Life Sciences Pungnap Dong filed Critical Neogentc Corp Convergence Innovation Building Asan Institute For Life Sciences Pungnap Dong
Priority claimed from PCT/KR2019/018617 external-priority patent/WO2020139027A1/en
Publication of EP3903805A1 publication Critical patent/EP3903805A1/en
Publication of EP3903805A4 publication Critical patent/EP3903805A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
EP19902677.4A 2018-12-28 2019-12-27 Immunopotentiating or anticancer activity-augmenting composition comprising mal-expressed stem cell like memory t cell as active ingredient Withdrawn EP3903805A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180172298 2018-12-28
PCT/KR2019/018617 WO2020139027A1 (en) 2018-12-28 2019-12-27 Immunopotentiating or anticancer activity-augmenting composition comprising mal-expressed stem cell like memory t cell as active ingredient

Publications (2)

Publication Number Publication Date
EP3903805A1 EP3903805A1 (en) 2021-11-03
EP3903805A4 true EP3903805A4 (en) 2022-09-14

Family

ID=71601017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19902677.4A Withdrawn EP3903805A4 (en) 2018-12-28 2019-12-27 Immunopotentiating or anticancer activity-augmenting composition comprising mal-expressed stem cell like memory t cell as active ingredient

Country Status (3)

Country Link
EP (1) EP3903805A4 (en)
KR (2) KR102179381B1 (en)
CN (1) CN113677361A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102568745B1 (en) * 2021-05-18 2023-08-24 주식회사 바이오솔루션 Immune cells with enhanced extracellular vesicle secretion and immunotherapy using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332583T2 (en) * 1992-09-01 2003-11-20 Dana-Farber Cancer Institute, Inc. MASPIN- A NEW SERPIN WITH TUMOR REPRESSIVE ACTIVITY
ES2200678B1 (en) * 2002-03-14 2005-06-01 Consejo Sup. Investig. Cientificas USE OF BAD PROTEIN AS A TUMOR MARKER.
KR20090033775A (en) 2007-10-01 2009-04-06 김동청 Immuno-potentiating composite comprising hexane extract of ginseng as an active ingredient
PT2283154E (en) * 2008-04-14 2013-08-29 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg Mal and cadm1 promoter methylation a molecular diagnostic marker for hpv-induced invasive cervical cancers and their high-grade precursor lesions
JP2012031076A (en) * 2010-07-29 2012-02-16 Ltt Bio-Pharma Co Ltd Cancer stem cell differentiation inducer
JP2013111053A (en) * 2011-11-30 2013-06-10 Kyoto Univ Method of searching biomarker, and method of detecting cancer, using biomarker found by the same
KR20170068504A (en) * 2014-10-08 2017-06-19 노파르티스 아게 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTON OLGA ET AL: "An essential role for the MAL protein in targeting Lck to the plasma membrane of human T lymphocytes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, no. 13, 22 December 2008 (2008-12-22), US, pages 3201 - 3213, XP055948783, ISSN: 0022-1007, DOI: 10.1084/jem.20080552 *

Also Published As

Publication number Publication date
KR20200128496A (en) 2020-11-13
KR20200083318A (en) 2020-07-08
EP3903805A1 (en) 2021-11-03
CN113677361A (en) 2021-11-19
KR102179381B1 (en) 2020-11-16

Similar Documents

Publication Publication Date Title
IL274200A (en) Methods, compositions, and implantable elements comprising active cells
EP3638248A4 (en) Conjugates of active pharmaceutical ingredients
EP3604301A4 (en) 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
EP3972584A4 (en) Nanoemulsion compositions comprising biologically active ingredients
EP3351254A4 (en) Composition for preventing or treating inflammatory diseases, containing, as active ingredient, stem cells overexpressing sod3
EP3784707A4 (en) Stable polyurea microcapsule compositions
EP3580208A4 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP3486252A4 (en) Composition for cell protection containing cyclo histidine-proline as active ingredient
EP3659611A4 (en) Composition for preventing or treating osteoporosis containing exosomes extracted from stem cells as active ingredient
EP3590497A4 (en) Stabilized external use agent comprising thymosin beta-4 as effective ingredient
EP3613419A4 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
EP3354254A4 (en) Skin whitening composition containing beta-mangostin as active ingredient
EP3827810A4 (en) Cosmetic composition containing galactomyces-derived exosome as active ingredient
EP3694330A4 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3385254A4 (en) 1,2,3-triazole derivative and insecticide/acaricide having said derivative as active ingredient
EP3894408A4 (en) Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
EP3520614A4 (en) Nematode control composition comprising grammicin compound as active ingredient and use thereof
EP3694331A4 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3643295A4 (en) Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis
EP3868385A4 (en) Gastric cancer treatment composition comprising syt11 inhibitor as active ingredient
EP3449924A4 (en) Composition, crocins active site, and uses thereof
EP3668314A4 (en) Agricultural compositions containing structured surfactant systems
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP3610869A4 (en) Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
EP4166155A4 (en) Composition comprising pentapeptide as active ingredient

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220812

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220808BHEP

Ipc: G01N 33/50 20060101ALI20220808BHEP

Ipc: G01N 33/68 20060101ALI20220808BHEP

Ipc: A61K 35/17 20150101ALI20220808BHEP

Ipc: A61K 38/17 20060101AFI20220808BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230112